

B3

23. (amended) A method of treating fungal infections, said method comprising contacting the affected diseased sites with an amount of composition which comprises triclosan and a cationic antimicrobial compound which is effective to alleviate the symptoms of said fungal infection.

Kindly cancel claims 2-6, 8-17 and 26.

B4

Kindly add the following claims:

rule 126

-³¹₃₀. A method as defined in claim 20 wherein the composition consists essentially of triclosan and cetylpyridium chloride.

B4

³²₃₁. A method as defined in claim 28 wherein the composition consists essentially of triclosan and cetylpyridium chloride.--

REMARKS

The acceptance of the Terminal Disclaimer as obviating the obviousness double patenting rejection over U.S. 5,945,089 has been noted. A second Terminal Disclaimer is attached to this Amendment which disclaims any term of any patent issuing on the subject application, which would extend beyond the term of U.S. 5,855,872. The second Terminal Disclaimer obviates the basis of the double patenting rejection set forth on page 6 of the Office Action.

On page 7 of the Office Action, claims 1 and 23-30 were rejected under 35 U.S.C. §103(a) as being obvious as a whole from the combination of Takaoka (GB 2160099) taken in combination with the cationic antimicrobials such as in the non-patent literature, especially Levy(I), Cancro (III); Greenspan (IV); Poland (A); Ferretti et al. (9) (10); Costiala (Kostiala et al); Budtz-Jorgenson; Veb (East Germany 221080); Gluck (I); Gluck (II); Hill(EP679390) and Livingston (Canada